Pfizer (NYSE:PFE) and GSK (NYSE:GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to ...

Some justices may be skeptical of a bid by GSK, Pfizer and others to overturn ruling allowing lawsuits to proceed over claims ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

GlaxoSmithKline (GSK) and Pfizer filed a stipulation to dismiss with prejudice GSK’s litigation in the United States District ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Goldman Sachs said Monday that GSK (NYSE:GSK) is set for a 'positive ... (ACIP), which is tasked with endorsing Arexvy and Pfizer’s (NYSE:PFE) rival shot Abrysvo for a younger cohort of older ...